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ABSTRACT 
Background: The Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE) 
was the first large-scale, prospective clinical trial to show that cholesterol4owering 
therapy with pravastatin is effective in reducing the risk for cardiovascular 
events (CVEs) in elderly (aged _>60 years) patients with hypercholesterolemia. 
PATE also included a subgroup of patients with diabetes mellitus (DM). 
Object ive: The aim of this post hoc analysis was to assess the effects of long- 
term pravastatin therapy on cardiovascular outcomes in the subgroup of patients 
with DM compared with a subgroup without it. 
Methods: PATE was conducted at 50 hospitals, universities, and clinics across 
Japan. Patients were randomly allocated to 1 of 2 treatment groups: low-dose 
pravastatin (5 mg PO QD; L group) or standard-dose pravastatin (in Japan, 10 mg 
PO QD; S group). Treatment was given for 3 to 5 years. Serum cholesterol levels 
were measured and the prevalence of CVEs was determined. The primary end 
point of the study was the S:L risk ratio for fatal or nonfatal CVEs. The secondary 
end point was the effect of diabetic patients' glycemic ontrol on CVEs. 
Results: A total of 665 patients (527 women, 138 men; mean [SD] age, 72.8 
[5.7] years) were followed up for a mean of 3.9 years (range, 3-5 years). Among 
these, 199 patients had DM; 104 patients with DM were allocated to the L group and 
*The PATE Investigators are listed in Appendix I. 
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95 to the S group. Four hundred sixty-six patients did not have DM (L group, 
230 patients; Sgroup, 236 patients). Overall, between 3months and 3 years after 
the initiation of treatment, patients in the L group (mean dose, 4.5 mg/d) ex- 
perienced reductions from baseline total cholesterol level of 11% to 13%. Those 
in the S group (mean dose, 8.3 mg/d) experienced reductions from baseline 
of 15% to 17%. Decreases in low-density lipoprotein cholesterol (LDL-C) levels 
were 17% to 20% and 23% to 26% in the L and S groups, respectively. Statistically 
similar reductions were noted between patients with DM and those without it 
in response to either dose. The DM subgroup experienced 32 CVEs (L group, 17; 
S group, 15) compared with 39 CVEs (L group, 25; S group, 14) in the subgroup 
without DM. The S:L CVE risk ratio (primary end point) was 0.94 (95% CI, 0.46- 
1.92) in patients with DM and 0.54 (95% CI, 0.28-1.05) in those without DM; the 
differences between the treatment groups were not statistically significant. The 
risk for CVEs in patients with DM whose glycosylated hemoglobin concentrations 
were <8.0% and >8.0% were, respectively, 1.87-fold (95% CI, 1.09-3.20; P = 0.02) and 
3.794old (95% CI, 1.92-7.48; P < 0.01) higher than that in patients without DM. 
¢ondusions: In this post hoc analysis of the effects of long-term cholesterol- 
lowering therapy (low- and standard-dose pravastatin) on cardiovascular out- 
comes in elderly patients with DM, dose had no effect on the risk for CVEs in 
these patients as it did in those without DM. Poorer glycemic ontrol in patients 
with DM was related to a higher risk for CVEs. The lack of pravastatin efficacy 
found in the subgroup with DM may have been attributable to the small differ- 
ences in LDL-C levels found between the 2 treatment groups and/or the small 
sample size of the study. (Curr Ther Res Clin Exp. 2005;66:48-65) Copyright © 
2005 Excerpta Medica, Inc. 
gey words: PATE study, elderly patients, pravastatin, hyperlipidemia, dia- 
betes mellitus, prospective interventional trial. 
INTRODUCTION 
The Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE) 1 was the first 
large-scale, prospective clinical trial specifically designed to investigate the ef- 
fects of lowering serum levels of total cholesterol (TC) and low-density lipopro- 
tein cholesterol (LDL-C) on the risk for cardiovascular events (CVEs) in elderly 
patients with hypercholesterolemia. B sed on a MEDLINE search (key terms: 
hypercholesterolemia, intervention, and elderly people; years, 1980-2000), PATE 
was the first such study. 
Briefly, the study included male and female Japanese patients aged _>60 years 
with and without cardiovascular disease (CVD) and with hypercholesterolemia. 
Patients were randomly allocated to 1 of 2 treatment groups: low-dose pravastatin 
(5 mg PO QD; L group) or standard-dose pravastatin (in Japan, 10 mg PO QD; 
S group). Treatment was given for 3 to 5 years. The primary end point of PATE 
was the prevalence of CVEs, including ischemic heart disease, cerebrovascular 
disease, peripheral vascular disorder, and sudden cardiac death. 
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Because all of the patients in the study were at risk for CVEs due to their age 
and TC levels, no placebo group was included. The hypothesis of the study was 
that pravastatin would lower patients' TC and LDL-C levels. Because elderly 
patients commonly have reduced drug tolerance and their physicians often 
prescribe lower drug doses compared with younger patients, the rationale be- 
hind the study design was assessment of the effects of low- versus standard- 
dose therapy on clinical outcome. 
A total of 665 patients were enrolled (527 women, 138 men; mean [SD] age, 
72.8 [5.7] years; mean [SD] serum TC level, 253 [15] mg/dL; mean [SD] serum 
LDL-C level, 165 [24] mg/dL; L group, 334 patients; S group, 331 patients). Mean 
follow-up was 3.9 years. The mean pravastatin doses in the L and S groups were 
4.5 and 8.3 mg/d, respectively. 
Overall, between 3 months and 3 years after the initiation of treatment, 
the mean (SD) serum TC levels decreased 11% to 13% (from 253 [15] to 218 
[28] mg/dL) in the L group and 15% to 17% (from 253 [15] to 211 [27] mg/dL) in 
the S group (both, P < 0.01). In the same period, the mean (SD) LDL-C levels 
decreased 17% to 20% (from 164 [23] to 131 [27] mg/dL) in the L group and 23% 
to 26% (from 166 [25] to 127 [27] mg/dL) in the S group (both, P< 0.01). Forty- 
two CVEs occurred in the L group and 29 in the S group; the difference was 
statistically significant (P = 0.046). 
In addition to cholesterol lowering in reducing cardiovascular risk, evidence 
shows that diabetes mellitus (DM) may be associated with a markedly in- 
creased risk for CVEs, 2~ and it is widely recognized that established risk fac- 
tors for CVEs (eg, dyslipidemia, hypertension, obesity) are common in patients 
with DM. 7 Diabetic dyslipidemia in particular appears to be strongly linked to 
CVD. a Impaired glucose tolerance---an i dependent risk factor for CVD and an 
intermediate stage in the pathogenesis of type 2 DMg,l°--has been associated 
with the insulin resistance syndrome, which includes hypertension, a low high- 
density lipoprotein cholesterol (HDL-C) level, and an elevated serum triglyc- 
eride (TG) level, n'12 An elevated TG level has been shown to decrease LDL-C 
particle size 13 (which, in turn, has been shown to increase the atherogenicity 
of LDL-C 14,15) and to increase platelet release of plasminogen activator inhibi- 
tor 11~ (which has been shown to contribute to enhanced thrombosis17). Thus, it 
is of considerable interest o ascertain the effects of lowering TC and LDL-C on 
the occurrence of macrovascular bnormalities in DM. 
In a subanalysis 18of 586 patients aged 21 to 75 years with DM and impaired 
glucose tolerance included in the Cholesterol and Recurrent Events (CARE) 
trial, |9 pravastatin therapy was associated with a lower prevalence of recur- 
rent CVEs after myocardial infarction (MI) in this population compared with 
placebo (P = 0.05). The Scandinavian Simvastatin Survival Study (4S) 2° showed 
a similarly reduced risk in patients with elevated fasting plasma glucose levels 
or DM after cholesterol-lowering therapy in the setting of secondary prevention 
compared with placebo (P < 0.01). 21 The Heart Protection Study 22 also showed 
a decreased prevalence of CVEs in patients with DM with and without a history 
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of coronary heart disease or MI after cholesterol-lowering therapy with simva- 
statin compared with placebo (P < 0.05). 
PATE included 199 patients with DM. The present report is a post hoc analysis 
of the effects of long-term (at least 3 years) pravastatin therapy on cardiovascu- 
lar outcomes in this subgroup of patients compared with a subgroup without it. 
PATIENTS AND METHODS 
Study Design 
The design and major findings of PATE have been reported elsewhere. ] PATE 
was conducted at 50 hospitals, universities, and clinics across Japan. Patients 
were randomly allocated to the L or S group using an adaptive balancing method 
(biased coin minimization). History of CVD (MI, angina pectoris [AP], cerebro- 
vascular disease, or arteriosclerosis obliterans), TC level, and study site were 
balancing factors. 
Because the study was conducted before the International Conference on 
Harmonisation, Good Clinical Practice guidelines were established, verbal in- 
formed consent was obtained from eligible patients and was recorded in the 
medical records, and institutional review board approval of the study protocol 
was not sought at all of the study sites. However, the ethical aspects of the 
study were continually examined by the Monitoring Committee of the PATE 
Investigators. Although this trial was open-label, assessment of the end points 
was performed under investigator-blinded conditions. 
Patients with familial or secondary hypercholesterolemia and/or malignant 
neoplasia were excluded from the study. 
Patients who had coniirmed DM or were receiving antidiabetic drugs at en- 
rollment constituted the subgroup with DM; DM was diagnosed according to 
the criteria of the Japan Diabetes Society (Appendix 1123). Primary care physi- 
cians' patient interviews and clinical examination of results were used to deter- 
mine whether the patients met the criteria for inclusion in the DM subgroup. 
All other patients recruited in PATE constituted the subgroup without DM. 
Registration forms and records from follow-up indicated that patients with 
types 1 and 2 DM were included in the study, although all but 3 of these patients 
had type 2 DM. 
All antihyperlipidemic drugs, except for the study agent, were to be discontin- 
ued at least 3 months before the study. Other concomitant drugs (eg, antidia- 
betic drugs) were allowed. Twelve-hour fasting serum lipid levels (TC, HDL-C, 
and TG), blood pressure, and body weight were measured at baseline (month 0); 
at l, 3, and 6 months of pravastatin therapy; and every 6 months thereafter 
until study end. LDL-C levels were calculated using the Friedewald formula 24 
unless the TG level was >_400 mg/dL. Hypertension was defined as systolic/ 
diastolic blood pressure >_160/>-90 mm Hg 2S and/or the use of antihypertensive 
drugs. Routine physical examinations and laboratory analyses, including pe- 
ripheral blood cell count, and biochemistry (including hepatic and renal func- 
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tion tests and creatine kinase activity), were conducted by primary care physi- 
cians at intervals of no more than 6 months. 
During the follow-up period, physicians contacted patients by mail every 
3 months to determine compliance with pravastatin therapy. If a patient had 
discontinued therapy, his or her physician was to record the discontinuation 
date and the reason(s) for it. 
Primary care physicians provided general instructions for diet and exercise 
before the study. However, no further detailed instructions were given after the 
start of the study, and patients' diet and exercise habits were not investigated. 
The primary end point of PATE was the S:L risk ratio for fatal or nonfatal CVEs, 
including cerebrovascular disease, ischemic heart disease, peripheral vascular 
disease, and sudden cardiac death. Cerebrovascular disease included cerebral 
infarction, cerebral hemorrhage, transient ischemic attack, and subarachnoid 
hemorrhage. Ischemic heart disease included MI, AP, congestive heart failure 
due to ischemic heart disease, and arrhythmia requiring pharmacologic treat- 
ment. A patient was diagnosed with AP if he or she had chest pain or discomfort 
with all of the following characteristics: (1) it included any level of the sternum; 
(2) it occurred uring exertion or stress and usually lasted at least 30 seconds; 
(3) on most occasions it resolved within 10 minutes of stopping or decreasing 
the intensity of exertion; and (4) it was usually relieved within 2 to 5 minutes 
after receiving nitroglycerine, if nitroglycerine was used. All outcome variables 
were assessed based on the end point defined in the appendix of the original 
PATE study) 
The effect of the extent of glycemic ontrol on the risk for CVEs (secondary 
end point) was assessed by measuring the prevalence of CVEs in patients with 
DM whose glycosylated hemoglobin (HbAle) concentration was >8.0% versus 
that in patients whose concentration was <8.0%. HbAlc concentration 8.0% was 
selected as the cutoff point because it is generally considered indicative of un- 
controlled DM. 
Potential end points were reviewed and classified by the members of a 
Case/Event Evaluation Committee of the study investigators. Members of this 
committee were blinded to the identities and treatment assignments of the 
patients. In cases in which the first reporting by the physicians of a CVE was 
inadequate, additional information required to determine whether an event was 
a CVE (eg, electrocardiography, brain computed tomography, coronary angiog- 
raphy) was requested by the Case/Event Evaluation Committee. 
Statistical Analysis 
Analyses were performed on an intent-to-treat basis. Baseline characteristics 
were compared between groups using the Wiicoxon, KruskaI-Wallis, or chi-square 
test. Changes in serum lipid levels before and after the initiation of pravastatin 
therapy were assessed with the least squares means calculated using general lin- 
ear models. Differences between patients with and without DM and between the 
2 treatment groups were assessed using repeated-measures analysis of variance. 
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For the primary end point in patients with and without DM and overall, the Cox 
regression analysis was used to assess the effectiveness of standard-dose prava- 
statin compared with low-dose pravastatin adjusted for age, sex, DM, smoking 
history, hypertension, and history of CVD. Cardiovascular risk in patients with 
DM was also assessed using the Cox regression analysis adjusted for treatment 
group, age, sex, smoking history, hypertension, and history of CVD. 
P < 0.05 (2-sided) was considered statistically significant. All statistical anal- 
yses were performed using SAS software version 6.12 (SAS Institute Inc., Cary, 
North Carolina). 
RESULTS 
Patient Population 
A total of 703 patients were enrolled in the original PATE) After randomiza- 
tion, 38 patients were excluded for the following reasons: no attendance athos- 
pital after registration (19 patients), withdrawal of informed consent (6), anoth- 
er cholesterol-lowering regimen in use at the start of pravastatin treatment (4), 
duplicate ntry (3), active malignancy (3), familial hypercholesterolemia (2),
and secondary hypercholesterolemia due to hypothyroidism (1). The remain- 
ing 665 patients (527 women, 138 men; mean [SD] age, 72.8 [5.71 years) were fol- 
lowed up (Table I). The L group contained 334 patients (104 with DM, 230 with- 
out it); the S group, 331 patients (95 with DM, 236 without it). The numbers of 
patients with and without DM were statistically similar between the 2 treatment 
groups. 
No significant differences in age, HbAI¢ concentration, or presence of cardio- 
vascular isk factors (eg, hypertension, history of CVD, smoking) were found 
between the 2 treatment groups. Mean (SD) HbAI¢ concentrations in the pa- 
tients with DM were 6.9% (1.2%) (range, 4.8%-10.6%) in the L group and 6.9% 
(1.1%) (range, 5.1%-10.1%) in the S group. The percentages of patients with 
DM and a history of CVD were 26.9% (28/104) and 17.9% (17/95) in the L and 
S groups, respectively. The percentage of S-group female patients without DM 
was higher than those with DM (P = 0.049). 
The clinical profile of the patients with DM (n = 199), including their concomi- 
tant drug regimens (eg, antihypertensive drugs, nitrites, antidiabetic drugs) is 
shown in Table II. Major DM complications present in these patients included 
diabetic nephropathy (L group, 1.9% [2/104]; S group, 2.1% [2/95]) and diabetic 
retinopathy (L group, 0; S group, 1.1% [1/95]). A total of 44.2% (46/104) of pa- 
tients with DM in the L group and 45.1% (43/95) in the S group were receiving 
antihypertensive drugs. The numbers of patients receiving antihypertensive 
drugs were statistically similar between the L and S groups. The proportions of 
patients receiving hydrochlorothiazide w re 1.9% (2/104) and 1.1% (1/95) in the 
L and S groups, respectively. 
During the follow-up period, the mean pravastatin doses were 4.5 and 8.3 mg/d 
in the L and S groups, respectively. Patients who discontinued treatment were 
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Table II. Diabetes mellitus (DM) type, complications, and concomi- 
tant drug use in patients (no. [%]) in the Pravastatin Anti- 
atherosclerosis Trial in the Elderly.* 
Variable L Group (n = 104) S Group (n = 95) 
DM type 
I I (I.0) 2 (2.1) 
2 103 (99.0) 93 (97.9) 
Complications 
Diabetic nephropathy 2 (I .9) 2 (2.1) 
Diabetic retinopathy 0 (0.0) 1 (1.1) 
Drug use 
Antihypertensive drugs 
CCB 34 (32.7) 36 (37.9) 
ACEI 13 (12.5) 9 (9.5) 
Beta-blocker 4 (3.8) 4 (4.2) 
Hydrochlorothiazide 2 (I .9) I (I .I) 
Alpha-blocker I (I.0) 5 (5.3) 
Alpha- and beta-blocker I (I.0) 3 (3.2) 
Sulfonylureas 45 (43.3) 35 (36.8) 
Nitrites 4 (3.8) I (I .I) 
Insulin 3 (2.9) 8 (8.4) 
/ = low-dose pravastatin; S = standard-dose pravastatin; CCB = calcium channel blocker; 
ACEI = angiotensin-converting enzyme inhibitor. 
*No significant between-group differences were found. 
included in the calculation of the mean dose given in the S group (8.3 rag/d). The 
total discontinuation rate was 23.9% (L group, 21.3%; S group, 26.5%). 
Total DM patients and total non-DM patients howed similar percent reduc- 
tions in serum TC and LDL-C levels (Figure 1A, B). Furthermore, both DM and 
non-DM patients experienced similar reductions in TC and LDL-C in response 
to either low- or standard-dose pravastatin (Figure 1C-~. A significant dif- 
ference (P < 0.01) between the L and S groups was seen in DM patients 
(Figure 1C, D) and non-DM patients (Figure 1E, F). 
At the end of follow-up, in the L group of patients with DM, the mean (SD) 
serum TC level decreased from 254 (16) to 217 (27) mg/dL, and LDL-C from 
160 (24) to 131 (26) mg/dL. In the S group, the mean (SD) TC level decreased 
from 254 (15) to 208 (28) mg/dL, and LDL-C from 162 (25) to 125 (25) mg/dL. 
LDL-C decreased to <100 mg/dL in 8.7% (9/104) of patients with DM receiving 
the low dose, and 13.7% (13/95) of patients with DM receiving the standard 
dose. 
The subgroup with DM experienced 32 CVEs compared with 39 CVEs in the 
subgroup without DM. In the subgroup with DM, 17 CVEs occurred in patients 
receiving the low dose, and 15 CVEs in patients receiving the standard ose. 
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Figure 1. Least squares mean (SE) percentage changes in total cholesterol (TC) (A, C, E) 
and low-density lipoprotein cholesterol (LDL-C) (B, D, F) over t ime in 
patients in the Pravastatin Anti-atherosclerosis Trial in the Elderly. 1 DM = 
diabetes mellitus; L = low-dose pravastatin; S = standard-dose pravastatin. 
C-F, significant difference (P < 0.01) between the L and S groups. 
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In the subgroup without DM, 25 and 14 CVEs occurred in patients receiving 
the low and standard oses, respectively. 
The S:L CVE risk ratio [or the prevalence o[ [atal or non[atal CVEs was 0.94 
(95% CI, 0.46-1.92) in the subgroup with DM and 0.54 (95% CI, 0.28-1.05) in the 
subgroup without DM. The S:L risk ratio [or the overall population was 0.70 (95% 
CI, 0.43-1.12) (Figure 2). For the combined prevalence o[ MI, AP, and death from 
any cause, the S:L risk ratios were 0.54 (95% CI, 0.18-1.63) and 0.79 (95% CI, 
0.24-2.55) in the subgroups with and without DM, respectively. None o[ the di[- 
[erences were statistically signi[icant. In patients with DM and a history o[ CVD, 
the S:L hazard ratio was 0.35 (95% CI, 0.06-1.93), whereas in patients with DM 
and without a history o[ CVD, the S:L hazard ratio was 1.23 (95% CI, 0.05-2.85). 
The relative risk (RR) [or CVEs in the DM subgroup, adjusted [or dose 
group, age, sex, and CVD risk [actors, was 1.87-[old (95% CI, 1.09-3.20; P = 0.02) 
higher in patients with HbAlc <8.0% and 3.79-[old (95% CI, 1.92-7.48; P < 0.01) 
higher in patients with HbAle _>8.0% than that observed in the subgroup without 
DM (Figure 3). When the risk for CVEs in patients with neither DM nor a history 
o! CVD was assigned a relerence value o[ 1, the RR in patients with DM but with- 
out a history o[ CVD (calculated in the same manner) was 3.34 (95% CI, 
1.77-6.31; P< 0.01). In patients without DM but with a history o[ CVD, the RR 
was 3.57 (95% CI, 1.88-6.78; P < 0.01). In patients with DM and a history o! 
CVD, the RR was 3.73 (95% CI, 1.57-8.86; P < 0.01). 
All Patients 
(665 patients, 71 events) 
Patients Without DM 
(466 patients, 39 events) 
Patients with DM 
(199 patle nts, 32 events) 
0 0.5 1.0 1.5 2.0 
I A 
v 
A 
v 
I @ 
Favoring the S Group Favoring the L Group 
Figure 2. Risk ratios (95% CI) for the prevalence of fatal and nonfatal cardiovascular 
events (primary end point) in the Pravastatin Anti-atherosclerosis Trial in the 
Elderly. 1 Risk ratios were calculated using Cox regression analysis adjusted 
for age, sex, diabetes mellitus (DM), smoking history, hypertension, and his- 
tory of cardiovascular disease. S = standard-dose pravastatin; L = low-dose 
pravastatin. No significant between-group differences were found. 
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Patients with DM Patients with DM Patients 
and HbAlc and HbAlc Without DM 
<8.0% _>8.0% 
Risk ratios (RRs) (95% CI) for cardiovascular events. 1Gly¢osylated hemoglobin 
(HbAlc) concentrations were measured on enrollment. RRs were calculated 
from Cox regression analysis adjusted for group, age, sex, smoking history, 
hypertension, and history of cardiovascular disease. *P = 0.02 versus patients 
without diabetes mellitus (DM); tp < 0.01 versus patients without DM. 
Table HI shows the baseline characteristics of 2 subsets of patients with DM (ie, 
HbAlc <8.0% vs HbAlc >8.0%) compared with patients without DM. Because their 
basdine I-lbAlc concentrations were not measured, 7 patients with DM were exclud- 
ed from the analysis of the dfect of the extent of glycemic ontrol on CVE prevalence. 
No significant within-group differences in age or serum lipid levels were observed. 
To lerab i l i ty  
In PATE, 1 the prevalence ofadverse vents other than CVEs and malignant dis- 
ease was similarly low in the L group (19 events in 5.4% [ 18/334] of patients) and 
the S group (26 events in 6.0% [20/331] of patients). The most common adverse 
drug reactions observed in the study were a slight elevation in creatine kinase 
activity (6 cases in the L group; 12 in the S group) and gastrointestinal symptoms 
(5 cases in the L group; 6 in the S group). Forty-two f 45 adverse vents were 
mild, but 3 events were moderate (L group, decreased peripheral leukocyte 
count [from 3900 to 2400 ceiis/pL in 1 patient]; S group, increased blood urea 
nitrogen [from 20 to 27 mg/dL in 1 patient; from 21 to 29 mg/dL in 1 patient). All 
3 of the moderate adverse vents resolved on continuation of drug therapy. No 
serious adverse vents were reported in PATE. The prevalence of adverse drug 
reactions was statistically similar between the groups with and without DM. 
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Table III. Baseline demographic and clinical characteristics of patients in the Pravastatin 
Anti-atherosclerosis Trial in the Elderly. 
Patients with DM* 
HbAlc <8.0% HbAlc >_8.0% Patients Without DM 
Characteristic (n = 152) (n = 40) (n = 466) 
Pravastatin dose, 
no. (%) 
Low 78 (51.3) 24 (60.0) 230 (49.4) 
Standard 74 (48.7) 16 (40.0) 236 (50.6) 
Demographic 
Age, mean (SD), y 72.5 (5.4) 72.9 (5.4) 72.9 (5.8) 
Sex, no. (%) 
Female 116 (76.3) 30 (75.0) 378 (81.1) 
Male 36 (23.7) 10 (25.0) 88 (18.9) 
Clinical 
Lipid levels, 
mean (SD), mg/dL 
TC 254 (1 5) 251 (1 5) 253 (15) 
HDL-C 57 (15) 57 (1 6) 55 (15) 
LDL-C 162 (24) 160 (25) 1 67 (24) t 
TG 152 (80) 160 (74) 1 52 (88) 
HbAle % 6.5 (0.8) 8.7 (0.7) - 
Risk factors, 
no. (%) 
HTN* 74 (48.7) 17 (42.5) 242 (51.9) 
History of CVD 28 (1 8.4) 11 (27.5) 1 32 (28.3) 
Smokers 14 (9.2) 4 (10.0) 39/460 § (8.5) 
DM = diabetes mellitus; HbAlc = glycosylated hemoglobin; TC = total cholesterol; HDL-C = high- 
density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides; HTN = 
hypertension; CVD = cardiovascular disease. 
*Seven patients with DM were excluded from this analysis because their baseline HbAlc levels were not 
measu red. 
tp = 0.03 versus patients with DM. 
*Hypertension was defined as systolic/diastolic blood pressure >160/L>90 mm Hg 2s and/or the use of 
antihypertensive drugs. 
§Data were unavailable in 6 patients. 
DISCUSSION 
DM is a significant risk factor for CVEs in elderly patients with hypercholester- 
olemia. SThe results of the present analysis uggest hat patients with DM have a 
similar risk for CVEs as those with a history of CVD. The risk was higher when 
glycemia was poorly controlled. Although the duration of DM in patients in PATE 
was not recorded, it has been shown to be proportional to the risk for CVEs. s Thus, 
glycemic ontrol is important in reducing the risk for CVD in elderly patients. 
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The CARE trial, 19 the 4S, 2°,21 and the Heart Protection Study 22 have shown 
that cholesterol-lowering therapy provides effective prevention of CVEs in pa- 
tients with and without DM. However, in PATE, 1 CVE risk reduction with 
pravastatin i patients with DM was less than that in patients without DM. TC 
and LDL-C levels were decreased in both subgroups, although the difference 
between the L and S groups was statistically significant (P < 0.01). 
The discontinuation rate among all patients in PATE was 23.9%, which is 
similar to the 4-year discontinuation rate of 24.7% observed in the similarly 
designed West of Scotland Coronary Prevention Study (WOSCOPS), 2G but lower 
than the 31.3% rate observed in the Helsinld Heart Study. 27 
The daily doses of pravastatin used in the 2 treatment groups in PATE were 
5 and 10 mg, a difference of 5 mg. This difference was smaller than that in the 
CARE triaP 9 (40 mg). In the present analysis, the decrease in LDL-C level in 
patients with DM was not small. Moreover, statins are known to have pleiotrop- 
ic effects. The decreased risk for CVEs may have been significant in both the 
L and S groups if a placebo group had been available for comparison. Also, had 
the LDL-C level been decreased more, a significant risk reduction may have 
been found. However, the risk reduction was not significant in either of the 
2 treatment groups, perhaps because of the small (6%) difference in LDL-C 
reduction observed between the 2 groups. Furthermore, no linear relationship 
was found between the degree of TC and LDL-C reduction and the risk for CVEs 
in CARE 19 or WOSCOPS, 2G in which pravastatin was used. 
The small difference between the doses given to the 2 groups in PATE may 
have obscured the expected CVE risk reduction in elderly patients with DM. The 
disease picture in elderly patients with DM and hypercholesterolemia is likely so 
complicated that cholesterol lowering alone may not reduce the risk for CVEs. 
As for the subgroup with DM, the number of patients with a history of CVD was 
statistically similar between the L and S groups. In patients with a history of 
CVD, the S:L hazard ratio was 0.35 (95% CI, 0.06-1.93), whereas in patients with 
no history of CVD, the S:L hazard ratio was 1.23 (95% CI, 0.53-2.85). The number 
of patients with DM was too small to analyze the impact of the difference in CVE 
risk in patients or to allow for further adequate analysis of CVE risk. 
The Pravastatin in Elderly Individuals at Risk of Cardiovascular Disease 
(PROSPER) study, ~ a large, randomized, placebo-controlled trial in which 
patients in the active-treatment arm received pravastatin 40 mg/d, showed 
that cholesterol-lowering therapy in elderly patients reduced the risk for CVD. 
Eleven percent of elderly patients in the PROSPER study had a history of DM. 
Compared with placebo, pravastatin carried a hazard ratio of 0.79 (P < 0.01) in 
the group of patients without a history of DM and 1.27 (P = NS) in the group 
in whom DM was reported. However, as in the present study, the number of 
patients with DM in the PROSPER study was too small to allow an accurate 
analysis of the effects of therapy. 
Freeman et a129 reported that patients receiving pravastatin had a significant- 
ly reduced risk for DM compared with placebo. It is unclear whether this effect 
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came about in PATE, because changes in glycemia were not recorded. Although 
patients with DM in the S group had a lower prevalence of CVEs than those in 
the L group, no clear conclusion could be reached regarding which dose is bet- 
ter for elderly patients with DM. In these patients, there are cardiovascular risk 
factors in addition to DM (eg, exaggerated platelet adhesiveness, impaired renal 
function), and these risk factors affect one another. Due to the small sample size 
and small differences in LDL-C levels, differences in CVE prevalence between 
the L and S groups in patients with DM were not significant. 
Study Umitations and Future Direction 
The results of this analysis uggest hat pravastatin is effective in reducing 
the risk for CVEs. However, due to nonsignificant differences in LDL-C reduction 
between the 2 treatment groups and the small sample size of the study, this 
study did not show the efficacy of pravastatin i  improving hypercholester- 
olemia. Further study will be necessary to confirm this finding. In addition, 
the influence of diet was not investigated in this analysis. In future studies, moni- 
toring diet and exercise habits in studies of low- versus standard-dose prava- 
statin may reveal an expected similarity in the changes in TC and LDL-C levels 
between treatment groups. 
It is clear that elderly patients with DM have an increased risk for CVD. It is 
hoped that the significance ofcholesterol-lowering therapy in such patients can 
be established. 
CONCLUSIONS 
In this post hoc analysis of the effect of long-term cholesterolqowering therapy 
(low- and standard-dose pravastatin) on cardiovascular outcomes in elderly pa- 
tients with DM, dose had no effect on the risk for CVEs in these patients as it 
did in those without DM. In addition, poorer glycemic ontrol in patients with 
DM was related to a higher isk for CVEs. The lack of pravastatin efficacy found 
in the subgroup with DM may have been attributable tothe small differences in
LDL-C levels found between the 2 treatment groups and/or the small sample 
size of the study. 
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Appendix I. The PATE Investigators. 
The PATE Investigators included: Tokyo Metropolitan Geriatric Hospital: H. Ito, 
A. Hattori, and T. Sato; Teikyo University School of Medicine: T. Teramoto, 
M. Kinoshita, and N. Hashizume; Tokyo University School of Medicine: Y. Ouchi, 
M. Akishita, K. Kozaki, K. Toba, Y. Hashimoto, Y. Horie, H. Sato, K. Tsukamoto, 
K. Atarashi, K. Motoyama, and T. Inoue; Juntendo University School of Medicine: 
T. Komiya, T. Tozima, and K. Mochizuki; Nippon Medical School: K. Ohba and 
H. Nakano; Keio University School of Medicine: H. Suzuki, H. Kumagai, and 
Y. Kanno; Aiso Clinic: Y. Aiso; Tokyo Teishin Hospital: S. Miyazaki; Toranomon 
Hospital: T. Murase; Tokyo Medical and Dental University: F. Numano, A. Tanaka, 
and E. Fujinuma; Tokyo Medical College: M. Takasaki, T. Iwamoto, S. Konjiki, 
Y. Osawa, K. Shin, Y. Yoneda, H. Arai, M. Tabata, and K. Hoshiai; Tokyo Women's 
Medical University, Daini Hospital: N. Kikuchi; Omori Red Cross Hospital: 
H. Aijima; Yokufukai Geriatric Hospital: A. Itagaki; Itabashi Medical Association 
Hospital: T. Saito; Kishibojin Hospital: H. Kawai; Nakazawa Clinic: M. Nakazawa; 
Tokyo-to Saiseikai Mukojima Hospital: S. Kitamura and T. Motomiya; Tokyo 
Metropolitan Tama Geriatric Hospital: T. Nakano; Kyorin University School of 
Medicine: M. Yamamoto and S. Mizukawa; KKR Tachikawa Hospital: K. Mori; 
Inagi Municipal Hospital: K. Koizumi; Shonan Hospital: T. Shiota; Yamachika 
Hospital: S. Endo; Sagamihara Kyodo Hospital: Y. Araki, T. Tochihara, T. Ito, and 
T. Kojima; Chiba University School of Medicine: N. Morisaki, S. Murano, J. Tashiro, 
J. Kobayashi, K. Yokote, and M. Shinomiya; Matsudo Municipal Hospital: T. Nishide; 
Juntendo Urayasu Hospital, Juntendo University School of Medicine: T. Kano; 
Jikei University Kashiwa Hospital: R. Watanabe; Omiya Medical Center, Jichi 
Medical School: M. Kawakami; National Ddense Medical College: T. Ishikawa; 
National Nishisaitama Chuo Hospital: 1". Saito, N. Kimura, and S. Hayashi; Suifu 
Hospital: K. litake; Jichi Medical School: 1". Kojo, N. Ueno, S. Kawashima, and 
M. Nishizawa; Dokkyo University School of Medicine: S. Tada, M. Fujikane, 
K. Hirata, S. Sunami, T. Soma, and M. Miyamoto; Rosai Hospital for Silicosis: 
M. Mishina; Gunma University School of Medicine: S. Kawazu, M. Shimizu, and 
S. Tomono; Takasaki National Hospital: N. Kanazawa; Yamanashi Prefecture 
Central Hospital: M. Nezu and Y. Noda; Shinshu University School of Medicine: 
T. Aizawa, H. Ohtsuka, and A. Sakurai; Mitsuke City Hospital: S. Takahashi; Chizu 
Municipal Hospital: E. Esumi, H. Moritani, N. Tokuyama, T. Kamesaki, and 
M. Kumada; Majima Hospital: K. Majima; Wada Clinic: H. Wada; Hoshi Clinic: 
A. Hoshi; Shonan Taiheidai Hospital: T. Chikazoe; Koto Hospital: H. Kuroda and 
T. Hishiki; Sekikawa Hospital: M. Kunii; and Kubojima Clinic: J. Ohshima. 
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Appendix II. Blood glucose levels (mg/dL) used to determine the presence of diabetes 
mellitus (DM) according to the Japan Diabetes Society. 23 
Venous Ca pillary Venous 
Diabetic Status Plasma Whole Blood Whole Blood 
Healthy/normal FPG <110 FPG <100 FPG <100 
and 1 hPG <1 60 and 1 hPG <160 and 1 hPG <140 
and 2hPG <120 and 2hPG <120 and 2hPG <110 
Neither normal Neither normal Neither normal 
nor diabetic nor diabetic nor diabetic 
FPG _>140 and/or FPG _>120 and/or FPG _<120 and/or 
2hPG _>200 2hPG ->200 2hPG _<180 
Borderline 
DM 
FPG = fasting plasma glucose; lhPG = 1-hour plasma glucose level on oral glucose (75 mg) tolerance 
test (OGI-I-); 2hPG = 2-hour plasma glucose level on OGI-I-. 
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